MaxCyte (MXCT) Q4 2025 Earnings Call Transcript

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: 17 hours ago

0mins

MXCT-3.11%

Should l Buy MXCT?

Source: NASDAQ.COM

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MXCT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MXCT

Wall Street analysts forecast MXCT stock price to rise

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.740

Low

4.94

Averages

6.92

High

8.89

Current: 0.740

Low

4.94

Averages

6.92

High

8.89

Craig-Hallum

Buy

downgrade

$7 -> $5

2026-03-25

New

Reason

Craig-Hallum

Price Target

$7 -> $5

AI Analysis

2026-03-25

New

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on MaxCyte to $5 from $7 and keeps a Buy rating on the shares. The firm notes the company reported an ostensibly weak quarter. However, Craig-Hallum points out that the company continues to make solid progress and that its fundamentals remain strong. In addition to supporting more late-stage programs than ever and launching a new product designed to build the early-stage customer pipeline, the firm believes that with the stock currently trading at a 50% discount to cash per share, the risk-to-reward profile is attractive.

BTIG

Buy

Neutral

downgrade

2025-08-11

Reason

BTIG

Price Target

2025-08-11

downgrade

Buy

Neutral

Reason

BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MXCT

Unlock Now

About MXCT

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

MAXCYTE INC REPORTS Q4 2025 TOTAL REVENUE OF $7.3 MILLION IN SEC FILING

19 hours agomoomoo

Company Overview: MAXCYT, Inc. reported a total revenue of $7.3 million for the fourth quarter of 2025.
Financial Filing: The revenue figures were disclosed in a recent SEC filing.

MaxCyte Q4 2025 Earnings Call Insights

8 hours agoseekingalpha

Revenue Decline: MaxCyte reported total revenue of $33 million for 2025, a 15% decrease from $38.6 million in 2024, with core revenue at $29.6 million, indicating significant challenges and revenue pressure in the market.
New Product Launch: The company launched the ExPERT DTx platform aimed at accelerating early-stage research and drug discovery, despite facing a $4 million revenue headwind from customer program consolidation, with 2026 total revenue guidance set between $30 million and $32 million.
Management Changes: Parmeet Ahuja will succeed Doug Swirsky as Chief Financial Officer effective March 30, reflecting strategic adjustments in the executive team to address current market challenges.
Cash Position: As of the end of 2025, MaxCyte had total cash and cash equivalents and investments of $155.6 million with no debt, demonstrating financial stability that supports future growth initiatives.

MaxCyte Reports 2025 Revenue Decline Amid Strategic Developments

12 hours agoYahoo Finance

Revenue Decline: MaxCyte's total revenue for 2025 was $33 million, reflecting a 15% decline from 2024, indicating financial challenges primarily due to customer program consolidations, with expectations of continued core revenue decline in 2026.
Core Revenue Drop: The core revenue for 2025 stood at $29.6 million, a 9% decrease year-over-year, with Q4 core revenue at $6.8 million, down 22% from Q4 2024, highlighting competitive pressures in the market.
High Gross Margin: Despite the revenue decline, MaxCyte achieved a gross margin of 78% in Q4 2025, up from 74% in Q4 2024, demonstrating effective cost management strategies that could support future profitability.
Financial Flexibility: By the end of 2025, MaxCyte maintained $155.6 million in cash with no debt, providing financial flexibility that supports future strategic investments and business development initiatives.